Fareva opens aerosol plant as part of $40m drug and OTC business investment

By Gareth Macdonald contact

- Last updated on GMT

iSotck/Paperkites
iSotck/Paperkites

Related tags: Drug, Pharmacology, Pharmaceutical drug

Fareva Group has set up an aerosol manufacturing facility at its site in Richmond, Virginia as part of a $40m (€37m) investment in its drug, OTC medicine and beauty care business.

The plant has capacity to make 100 million aerosols cans a year according to Fareva, which said it plans to hire 80 to 100 people. The next phase of the project will see the firm invest a further $20m to set up four additional manufacturing lines.

Fareva bought the Richmond site from Pfizer in 2011​. At present, it makes topical drugs, over the counter medicines - including the cough treatment Robitussin (guaifenesin) - and various consumer products for the North American market.

Related news

Related products

show more

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars